False Claims Act Recoveries in Fiscal Year 2025: The Cases Behind a Record Year

False Claims Act 2025 recoveries totaled $6,888,096,266 in settlements and judgments, the record annual result the Department of Justice announced on January 16, 2026. Behind the total were prescription records, drug-pricing data, contract bids, cybersecurity certifications and import declarations. If you recognize a gap between what your company did and what it told the government, the cases behind that headline matter more than the headline itself.

A Record Year Across Federal Programs

The annual total covers settlements and court judgments for the fiscal year ending September 30, 2025. The department’s statistical tables accompanying the release put the previous fiscal year’s total at $3,133,818,400.

Healthcare led the recoveries. Cases assigned primarily to the Department of Health and Human Services accounted for $5,721,536,531. The Department of Defense accounted for 633,927,500 dollars, and other federal agencies for 532,632,235 dollars.

The department’s health care summary identifies managed care, prescription drugs and medically unnecessary care as major areas. States also recovered money for their Medicaid programs in many of the same cases.

What Whistleblower Cases Contributed

Qui tam cases, brought by whistleblowers on the government’s behalf, accounted for $5,340,006,336 in settlements and judgments. Of that, $3,051,734,829 came from cases the United States joined or otherwise pursued, and $2,288,271,506 from cases whistleblowers continued after the government declined. Non-qui-tam matters accounted for 1,548,089,931 dollars.

Government intervention describes who takes responsibility for pursuing a whistleblower case. The recoveries show how much whistleblower-run cases contributed alongside those the government pursued.

Whistleblowers filed 1,297 new qui tam suits, exceeding the prior year’s record of 980. Of the new suits, 798 fell outside the Health and Human Services and Defense categories. The department also reported 401 new government investigations.

The tables separately report approximately $330 million in whistleblower share awards. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. The Congressional Research Service’s 2009 report, Qui Tam: The False Claims Act and Related Federal Statutes, describes the arrangement as rewarding people who bring cases in the government’s name with part of the proceeds.

What the Major Healthcare Cases Show

The annual fact sheet attached to the department’s announcement shows how prescription requirements, sales pitches and reported drug prices became the basis of the year’s cases.

Drugs Without Valid Prescriptions

A jury found Omnicare and its parent CVS liable for dispensing drugs without valid prescriptions to elderly and disabled residents of long-term care facilities. The companies billed Medicare, Medicaid and TRICARE for more than three million false claims. The court entered a $948.8 million judgment in August 2025.

Walgreens agreed to pay up to $350 million to resolve different allegations about dispensing controlled substances. The government alleged that prescriptions lacked a legitimate medical purpose or otherwise were invalid, including prescriptions for dangerous quantities of opioids and early refills.

Sales Claims and Reported Drug Prices

The department highlighted a $1.6 billion trial result against Janssen Products in a case pursued by whistleblowers over false and misleading claims about the safety and effectiveness of Prezista and Intelence. Their complaint described how promotional messages allegedly reached doctors through apparently spontaneous exchanges at dinner presentations:

That allegation puts a sales employee’s knowledge directly into the story. Someone who attended the dinner might have heard a question. Someone who helped arrange it could know why it was asked.

The fact sheet also highlighted a $289 million trial result against CVS Caremark for causing two Medicare Part D plans to report false and inflated generic-drug prices. Whistleblowers pursued that case too. Here, the disputed information was the price reported to the program.

Copays, Speaker Fees and Consulting Advice

Teva agreed to pay $425 million to resolve allegations that it paid Medicare patients’ copays for Copaxone while steadily raising the drug’s price. It separately agreed to pay $25 million over alleged generic-drug price fixing and kickbacks. The first case connects the patient’s payment at the pharmacy to the manufacturer’s pricing decisions.

Gilead agreed to pay $176 million to resolve allegations of speaker-program kickbacks. It admitted paying high-volume HIV-drug prescribers tens or hundreds of thousands of dollars in honoraria to prepare and present as speakers.

The allegations also reached outside drug manufacturers and pharmacies. McKinsey agreed to pay $323 million to resolve allegations that its advice to Purdue caused false claims for medically unnecessary OxyContin prescriptions and that it failed to disclose conflicts to the Food and Drug Administration arising from its concurrent work for Purdue. Advice upstream of the prescription became part of the civil case.

Government Contracts, Customs and Pandemic Relief

The year’s cases reached the information used to price contracts, certify computer security, calculate import duties and qualify for emergency funding. An invoice was often only the final request for payment.

Contract Prices Start Before the Invoice

Raytheon agreed to pay $428 million to resolve allegations that it supplied false cost and pricing data during military contract negotiations and double billed on a weapons maintenance contract. The government alleged that the conduct produced profits above negotiated rates.

The pricing records mattered before the government paid a bill. L3 Technologies’ separate $62 million settlement concerned allegations that it failed to disclose accurate, current and complete labor, material and other cost data for communications equipment. For employees who know how a bid was built, the estimates and disclosures can carry the story.

Cybersecurity Promises Meet the Audit Reports

The department reported more than $52 million from nine cybersecurity fraud settlements. These cases concerned security obligations attached to government contracts and grants.

Health Net Federal Services and its parent Centene agreed to pay $11.2 million over allegations that Health Net falsely certified cybersecurity compliance while administering health benefits for service members and their families. The government alleged failures to scan for known vulnerabilities and fix security flaws, alongside ignored reports from outside security auditors and the company’s internal audit department.

MORSECORP agreed to pay $4.6 million over alleged failures to meet contract security requirements. The government alleged that the company submitted an inaccurate security-controls score and did not promptly correct it or notify the government after a consultant identified the error. We see a familiar absurdity in that account: the score stayed reassuring after someone had explained why it was wrong.

Customs Duties Turn on Product and Origin

Grosfillex agreed to pay $4.9 million to resolve allegations that it disguised aluminum extrusions as sham furniture kits to evade duties. The government relies on importers’ descriptions to calculate what they owe. In this case, the alleged disguise was the packaging of the parts as something else.

The fact sheet also describes settlements over alleged misrepresentation of product type by Allied Stone and country of origin by Evolution Flooring. What the goods were and where they came from determined the duty bill. The department’s annual announcement also highlighted its cross-agency Trade Fraud Task Force, focused on these kinds of misrepresentations and disguises.

Pandemic Funding Had Conditions Attached

Pandemic-related matters produced more than 200 settlements and judgments exceeding $230 million during the fiscal year. The cases included alleged false employee and payroll information used to obtain Paycheck Protection Program loans, as well as claims involving COVID-19 testing and treatment.

Delta Air Lines agreed to an $8.1 million settlement over allegations that it paid compensation above limits it had accepted under the Treasury Department’s Payroll Support Program. The alleged problem concerned what the recipient did after receiving support. Payroll records could tell a different story from the conditions the company had agreed to honor.

Where the False Information Enters the Payment

An insider’s useful knowledge can sit with a supplier, a consultant, a sales team or a contractor’s security staff. The annual cases show how information from those businesses reaches a government payment or a duty bill.

Medisca’s $21.75 million settlement illustrates that connection. Compounding pharmacies buy ingredients to prepare prescriptions for patients who need specially made medicines. The government alleged that Medisca inflated the reported Average Wholesale Prices of ingredients so its pharmacy customers would receive higher federal reimbursement, often by thousands of dollars per prescription. The alleged overpayment began with the supplier’s price.

That is the connection we look for in the evidence behind a false claim: what the business knew, what it represented and how that information affected public money. A sales script, a pricing disclosure or an ignored audit can explain a transaction that looks ordinary from the invoice alone.

The Part of the Story You Know

Speak with our Whistleblower Experts about the pricing decisions, import declarations or ignored warnings you have seen. We work with you to build your strongest False Claims Act whistleblower case and bring in whistleblower lawyers who know the relevant drug-pricing, defense-contract, healthcare billing or customs fraud practice. We stay beside you as your case develops.